| Retatrutide | Ozempic (semaglutide) | |
|---|---|---|
| Drug class | GLP-1 + GIP + glucagon (triple) | GLP-1 only (single) |
| FDA status (2026) | Phase 3, not approved | Approved (diabetes; Wegovy for weight) |
| Reported weight loss | Up to ~24% (Phase 2) | Up to ~15% (STEP trials, Wegovy) |
| Availability | Clinical trials only | Prescription via licensed provider |
The headline difference is breadth of mechanism. Ozempic/Wegovy act on a single receptor (GLP-1); retatrutide adds GIP and glucagon activity, which appears to drive larger average weight loss in early studies. The trade-off is maturity and access: semaglutide is approved and widely available, while retatrutide remains investigational.
If you want a comparison against the other leading dual agonist, see retatrutide vs tirzepatide.
Get semaglutide with a licensed provider
A prescription matters: real reconstitution should be done with pharmacy-grade product and clinician guidance. These telehealth services handle the evaluation, prescription, and shipping.
Ro — weight loss program →Henry Meds →Frequently asked questions
Is retatrutide stronger than Ozempic?
Can I switch from Ozempic to retatrutide?
Dose with confidence — free tips by email
Practical dosing guides, reconstitution tips, and ways to save on your meds — about once a week, no fluff.